CAVO, MICHELE
CAVO, MICHELE
DIMEC - DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE
Radiologic findings of Fusarium pneumonia in neutropenic patients
In corso di stampa Sassi, Claudia; Stanzani, Marta; Lewis, Russell E.; Vianelli, Nicola; Tarsi, Andrea; Poerio, Antonio; Cavo, Michele; Battista, Giuseppe
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma
2025 Talarico, M.; Barbato, S.; Cattabriga, A.; Sacchetti, I.; Manzato, E.; Restuccia, R.; Masci, S.; Bigi, F.; Puppi, M.; Iezza, M.; Rizzello, I.; Mancuso, K.; Pantani, L.; Tacchetti, P.; Nanni, C.; Cavo, M.; Zamagni, E.
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia
2025 Musto, P.; Engelhardt, M.; van de Donk, N. W. C. J.; Gay, F.; Terpos, E.; Einsele, H.; Fernández de Larrea, C.; Sgherza, N.; Bolli, N.; Katodritou, E.; Gentile, M.; Royer, B.; Derudas, D.; Jelinek, T.; Zamagni, E.; Rosiñol, L.; Paiva, B.; Caers, J.; Kaiser, M.; Beksac, M.; Hájek, R.; Spencer, A.; Ludwig, H.; Cavo, M.; Bladé, J.; Moreau, P.; Mateos, M. V.; San-Miguel, J. F.; Dimopoulos, M. A.; Boccadoro, M.; Sonneveld, P.
Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients
2025 Salvestrini, Valentina; Conti, Gabriele; D'Amico, Federica; Cristiano, Gianluca; Candela, Marco; Cavo, Michele; Turroni, Silvia; Curti, Antonio
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
2025 Mancuso, Katia; Barbato, Simona; Talarico, Marco; Tacchetti, Paola; Zamagni, Elena; Cavo, Michele
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma
2024 Tacchetti, P.; Talarico, M.; Barbato, S.; Pantani, L.; Mancuso, K.; Rizzello, I.; Zamagni, E.; Cavo, M.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
2024 Hungria, V.; Robak, P.; Hus, M.; Zherebtsova, V.; Ward, C.; Ho, P. J.; Ribas de Almeida, A. C.; Hajek, R.; Kim, K.; Grosicki, S.; Sia, H.; Bryant, A.; Pitombeira de Lacerda, M.; Martinez, G. A.; Balari, A. M. S.; Sandhu, I.; Cerchione, C.; Ganly, P.; Dimopoulos, M.; Fu, C.; Garg, M.; Abdallah, A. -O.; Oriol, A.; Gatt, M. E.; Cavo, M.; Rifkin, R.; Fujisaki, T.; Mielnik, M.; Pirooz, N.; Mckeown, A.; Mcnamara, S.; Zhou, X.; Nichols, M.; Lewis, E.; Rogers, R.; Baig, H.; Eccersley, L.; Roy-Ghanta, S.; Opalinska, J.; Mateos, M. -V.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
2024 Dimopoulos, M. A.; Beksac, M.; Pour, L.; Delimpasi, S.; Vorobyev, V.; Quach, H.; Spicka, I.; Radocha, J.; Robak, P.; Kim, K.; Cavo, M.; Suzuki, K.; Morris, K.; Pompilus, F.; Phillips-Jones, A.; Zhou, X. L.; Fulci, G.; Sule, N.; Kremer, B. E.; Opalinska, J.; Mateos, M. -V.; Trudel, S.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
2024 Mateos, Maria Victoria; Weisel, Katja; Terpos, Evangelos; Delimpasi, Sossana; Kastritis, Efstathios; Zamagni, Elena; Delforge, Michel; Ocio, Enrique; Katodritou, Eirini; Gay, Francesca; Larocca, Alessandra; Leleu, Xavier; Otero, Paula Rodriguez; Schjesvold, Fredik; Cavo, Michele; Dimopoulos, Meletios A.
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma
2024 Tacchetti, Paola; Barbato, Simona; Mancuso, Katia; Zamagni, Elena; Cavo, Michele
Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells
2024 Pensato V.; Laginestra M.A.; Falvo P.; Orecchioni S.; Talarico G.; De Marchi E.; Bruno S.; Mongiorgi S.; Mitola G.; Bertolini F.; Adinolfi E.; Cavo M.; Curti A.; Salvestrini V.
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients
2024 Vigliotta, Ilaria; Solli, Vincenza; Armuzzi, Silvia; Martello, Marina; Poletti, Andrea; Taurisano, Barbara; Pistis, Ignazia; Mazzocchetti, Gaia; Borsi, Enrica; Pantani, Lucia; Marzocchi, Giulia; Testoni, Nicoletta; Zamagni, Elena; Terracciano, Mario; Tononi, Paola; Garonzi, Marianna; Ferrarini, Alberto; Manaresi, Nicolò; Cavo, Michele; Terragna, Carolina
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study
2024 Mancuso, K.; Mina, R.; Rocchi, S.; Antonioli, E.; Petrucci, M. T.; Fazio, F.; Gozzetti, A.; Salvini, M.; Cartia, C. S.; Bertuglia, G.; Patriarca, F.; Dalla Palma, A. B.; Barbato, S.; De Cicco, G.; Bigi, F.; Favero, E.; Tacchetti, P.; Pantani, L.; Rizzello, I.; Puppi, M.; Talarico, M.; Solli, V.; Kanapari, A.; Cavo, M.; Zamagni, E.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
2024 Sonneveld P.; Dimopoulos M.A.; Boccadoro M.; Quach H.; Ho P.J.; Beksac M.; Hulin C.; Antonioli E.; Leleu X.; Mangiacavalli S.; Perrot A.; Cavo M.; Belotti A.; Broijl A.; Gay F.; Mina R.; Nijhof I.S.; Van De Donk N.W.C.J.; Katodritou E.; Schjesvold F.; Sureda Balari A.; Rosiñol L.; Delforge M.; Roeloffzen W.; Silzle T.; Vangsted A.; Einsele H.; Spencer A.; Hajek R.; Jurczyszyn A.; Lonergan S.; Ahmadi T.; Liu Y.; Wang J.; Vieyra D.; Van Brummelen E.M.J.; Vanquickelberghe V.; Sitthi-Amorn A.; De Boer C.J.; Carson R.; Rodriguez-Otero P.; Bladé J.; Moreau P.
Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cells
2024 Corradi, G.; Forte, D.; Cristiano, G.; Polimeno, A.; Ciciarello, M.; Salvestrini, V.; Bandini, L.; Robustelli, V.; Ottaviani, E.; Cavo, M.; Ocadlikova, D.; Curti, A.
Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System
2024 Sparano, F.; Giesinger, J. M.; Gaidano, G.; Anota, A.; Cavo, M.; Brini, A.; Voso, M. T.; Venditti, A.; Perrone, F.; Di Maio, M.; Luppi, M.; Baron, F.; Platzbecker, U.; Fazi, P.; Vignetti, M.; Efficace, F.
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
2024 Delforge M.; Patel K.; Eliason L.; Dhanda D.; Shi L.; Guo S.; Marshall T.S.; Arnulf B.; Cavo M.; Nooka A.; Manier S.; Callander N.; Giralt S.; Einsele H.; Ailawadhi S.; Popa McKiver M.; Cook M.; Rodriguez-Otero P.
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
2024 Martello, Marina; Solli, Vincenza; Mazzocchetti, Gaia; Solimando, Antonio Giovanni; Bezzi, Davide; Taurisano, Barbara; Kanapari, Ajsi; Poletti, Andrea; Borsi, Enrica; Armuzzi, Silvia; Vigliotta, Ilaria; Pistis, Ignazia; Desantis, Vanessa; Marzocchi, Giulia; Rizzello, Ilaria; Pantani, Lucia; Mancuso, Katia; Tacchetti, Paola; Testoni, Nicoletta; Nanni, Cristina; Zamagni, Elena; Cavo, Michele; Terragna, Carolina
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review
2024 Bigi F.; Manzato E.; Barbato S.; Talarico M.; Puppi M.; Masci S.; Sacchetti I.; Restuccia R.; Iezza M.; Rizzello I.; Sartor C.; Mancuso K.; Pantani L.; Tacchetti P.; Cavo M.; Zamagni E.
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
2024 Mateos, M. -V.; Engelhardt, M.; Leleu, X.; Mesa, M. G.; Cavo, M.; Dimopoulos, M.; Bianco, M.; Merlo, G. M.; Porte, C. L.; Richardson, P. G.; Moreau, P.